16 completed, 2 active not recruiting, 2 not yet recruiting, 2 recruiting. 12 Phase 2, 10 Phase 3, 1 Phase 1, 1 Phase 4.
Follow Atrasentan: new trials by email Literature Review of Atrasentan trials Research Report on Atrasentan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 340 | 2026-12-01 | 2026-09-30 |
| Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN) atrasentan - IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN) | Phase 4 | Not yet recruiting | University of Illinois at Chicago | 20 | 2026-09-29 | 2026-09-21 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Drug: Atrasentan - Berger Disease, Bergers Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 28 | 2026-08-06 | 2026-11-06 |
| A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US No intervention, Other treatment, Iptacopan - Immunoglobulin A Nephropathy | Recruiting | Novartis Pharmaceuticals | 300 | 2025-03-04 | 2025-06-17 | |
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 54 | 2023-07-20 | 2026-07-20 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
| Atrasentan in Patients With IgA Nephropathy Atrasentan, Placebo, Zigakibart - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 404 | 2020-12-11 | 2026-06-04 |
| Atrasentan Spermatogenesis and Testicular Function Atrasentan - Nephropathy, Diabetes | Phase 2 | Completed | AbbVie | 20 | 2015-04-06 | 2019-05-07 |
| Study Of Diabetic Nephropathy With Atrasentan Atrasentan, Placebo - Diabetic Nephropathy | Phase 3 | Terminated | AbbVie | 5107 | 2013-05-17 | 2019-04-24 |
| A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy Atrasentan, Placebo - Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 48 | 2011-08-01 | 2013-10-25 |
| Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan Atrasentan low dose group, Atrasentan high dose group, Atrasentan placebo group - Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 58 | 2011-08-01 | 2017-08-29 |
| Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor Atrasentan, Placebo - Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 149 | 2011-04-01 | 2013-08-28 |
| A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD - Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 92 | 2009-06-01 | 2018-06-06 |
| S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy atrasentan hydrochloride, docetaxel, prednisone - Metastatic Cancer, Prostate Cancer | Phase 3 | Completed | SWOG Cancer Research Network | 1038 | 2006-08-01 | 2021-10-27 |
| Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer atrasentan hydrochloride - Kidney Cancer | Phase 2 | Completed | Eastern Cooperative Oncology Group | 180 | 2003-07-14 | 2023-06-22 |
| Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma atrasentan hydrochloride, doxil - Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 15 | 2003-05-01 | 2012-05-23 |
| Atrasentan in Treating Patients With Prostate Cancer atrasentan hydrochloride - Prostate Cancer | Phase 3 | Completed | Abbott | 2002-09-01 | 2011-02-21 | |
| Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma atrasentan hydrochloride - Brain and Central Nervous System Tumors | Phase 1 | Completed | National Cancer Institute (NCI) | 2002-06-01 | 2009-01-13 | |
| Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure Atrasentan - Prostatic Neoplasms | Phase 2 | Completed | Abbott | 200 | 2002-05-01 | 2006-08-15 |
| Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone Atrasentan, Zoledronic Acid (Zometa) - Prostate Cancer, Adenocarcinoma of the Prostate | Phase 2 | Completed | Massachusetts General Hospital | 44 | 2001-12-01 | 2010-05-10 |
Showing 20 of 25. Sign in to see all of them.
Glomerulonephritis, IGA (8) · Diabetic Nephropathies (7) · Prostatic Neoplasms (7) · Renal Insufficiency, Chronic (7) · Kidney Diseases (5) · Proteinuria (4) · Urologic Diseases (4) · Glomerulonephritis (3) · Diabetes Mellitus (2) · Adenocarcinoma (1) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Central Nervous System Neoplasms (1)
Novartis Pharmaceuticals (7) · Abbott (5) · AbbVie (prior sponsor, Abbott) (4) · AbbVie (2) · Eastern Cooperative Oncology Group (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · SWOG Cancer Research Network (1) · University of Illinois at Chicago (1) · Vanderbilt-Ingram Cancer Center (1)
United States (21) · Spain (7) · Canada (6) · Australia (5) · France (5) · Italy (5) · United Kingdom (5) · Germany (4) · South Korea (4) · Japan (3) · Netherlands (3) · New Zealand (3) · Poland (3) · Taiwan (3) · Austria (2)
Blai Coll, MD (2) · Darryl Sleep, M.D. (2) · Amir Lerman, M.D. (1) · Anand Srivastava, MD, MPH (1) · David I. Quinn, MD (1) · Dennis Andress (1) · Gary Gordon, M.D. (1) · Gary Gordon, MD (1) · Gary Gordon, MD, PhD (1) · Maha Hadi A. Hussain, MD (1) · Mark Garzotto, MD (1) · Marta Crispens, MD (1) · Matthew Smith, MD, PhD (1)
PMID 28756065, PMID 37716952, PMID 41442197, PMID 18477765, PMID 20733096, PMID 23871417, PMID 24565955, PMID 24616308, PMID 24722445, PMID 26153128, PMID 30995972, PMID 33270906, PMID 33338269, PMID 34853062, PMID 35772861, PMID 37254256, PMID 37657768, PMID 37872654, PMID 38059359, PMID 38299639, PMID 39460694, PMID 39661119, PMID 39899371, PMID 40526444, PMID 40938675, PMID 41904616, PMID 42242268
2016 (1), 2023 (1), U10CA032102 (1)